These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 18787469)

  • 1. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J; Fuchs H; Niemann VT; Hoffmeister B
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
    Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
    Sasaki A; Kawano K; Inomata M; Shibata K; Matsumoto T; Kitano S
    Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
    Park IJ; Choi GS; Jun SH
    Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; Maruszyński M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study.
    Oussoultzoglou E; Rosso E; Fuchshuber P; Stefanescu V; Diop B; Giraudo G; Pessaux P; Bachellier P; Jaeck D
    Arch Surg; 2008 Dec; 143(12):1150-8; discussion 1158-9. PubMed ID: 19075165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers in patients with relapse of colorectal carcinoma.
    Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
    Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
    Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
    Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
    Kumar Y; Gurusamy K; Pamecha V; Davidson BR
    Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.